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The behavioral effects of a selective A, adenosine receptor agonist 3-IB-MECA (N6-(3-iodobenzyl)-5’-N-methylcarboxamidoadenosine) in mice and 
the localization of radioligand binding sites in mouse brain were examined. Low levels of A, adenosine receptors were detected in various regions 
of the mouse brain (hippocampus, cortex, cerebellum, striatum), using a radioiodinated, high-affiity A,-agonist radioligand [‘251]AB-MECA 
(N6-(3-iodo-4-amino~~l)-S’-~-methylcarbox~idoad~osine). Scatchard analysis in the cerebellum showed that the & value for binding to A3 
receptors was 1.39 f 0.04 nM with a B,,,, of 14.8 + 2.1 fmol/mg protein. 3-JB-MECA at 0.1 mg&g i.p. was a locomotor depressant with > 50% 
reduction in activity. Althou~ selective A, or A, antagonists reversed locomotor depression elicited by selective A, or A, agonists, respectively, 
the behavioral depressant effects of 3-IB-MECA were unaffected. 3-IB-MECA also caused scratching in mice, which was prevented by coa&nin- 
istration of the histamine antagonist cyproheptadine. The demonstration of a marked behavioral effect of A, receptor activation suggests that the 
A, receptor represents a potential new therapeutic target. 
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1. INTRODUCTION 
The ~ntrally-mediated locomotor depressant effects 
of selective A, and Aza receptor agonists and their rever- 
sal by xanthine antagonists have been well documented 
[l-3,15]. Activation of both A, and A, receptors, by the 
A,-selective agonist CHA (N6-cyclohexyladenosine) and 
the A&-selective agonist APEC (Z[(Zaminoethyl- 
amino)carbonylethylphenylethylarnino]-5’-N-ethylcar- 
boxamidoadenosine), results in synergistic locomotor 
depression [3]. Similarly, although non-selective xan- 
thines, such as caffeine and theophylline, cause stimula- 
tion of locomotor activity [1,5], A,- or A&-selective xan- 
thines, such as CPX (1,3-dipropyl-8-cyclo~ntylxan- 
thine) and CSC (8-~3-chlorosty~l)~~eine), respec- 
tively, do not elevate locomotor activity except when 
coadministered [6]. Therefore, the functional roles of A, 
and Aza receptors in the CNS appear to be interrelated. 
A, receptors occur throughout the brain, and activation 
of presynaptic Al receptors results in decreased release 
of many stimulatory neurotransmitters ( ee [7]). In con- 
trast, A,, adenosine receptors occur mainly in the stria- 
turn and are closely associated with D,-dopamine recep- 
tors [7]. Activation of Aza receptors inhibits a dopamin- 
ergic pathway in the striatum. 
*Corresponding author. 
Recently, a third class of adenosine receptors (AJ has 
been cloned from rat brain [S]. A, receptors appear 
responsible for well-doc~ented stimulatory effects of 
adenosine agonists on release of i~~ato~ media- 
tors from mast cells [12,20]. As with A, receptors, cyclic 
AMP formation is inhibited by A3 receptor activation 
[8]. Phospholipid turnover is also stimulated by A3 re- 
ceptor activation [9]. Unlike A, and A, receptors, most 
alkylxanthines are ineffective as competitors in binding 
experiments at rat A,-receptors [8,10] or as antagonists 
in functional assays [8,9]. The cardiovascular (hypoten- 
sive) effects of A3 receptor stimulation have been sur- 
mised indirectly [13], through coadministration of a 
non-selective agonist, APNEA (1, Fig. l), and an antag- 
onist that blocks action only at A, and A, receptors. 
We recently introduced a class of highly selective ade- 
nosine A, agonists [I 11, including 3-IB-MECA (p-(3- 
iodobenzyl)-5’-~-methylcarbox~idoadenosine, 2, Fig. 
1). A closely related iodinated radioligand, [‘251]AB- 
MECA [9], 3, was found to bind to rat brain A3 recep- 
tors expressed in stably-transfected CHO cells with a Kd 
of 1 nM. However, this compound also binds to A1 
receptors in mouse and bovine brain. The in vivo effects 
of selective A3 agonists have not been characterized. 
Since stimulation of A, and Ah receptors produces de- 
monstrable behavioral effects, the impact of acute ad- 
~nistration of the A3 agonist 3-IB-MECA on locomo- 
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tor activity in mice was investigated in this study. The 
presence of A3 receptors in regions of the mouse brain 
was also demonstrated using radioligand binding. 
2. EXPERIMENTAL 
2.1. Agents 
3-IB-MECA and CSC were synthesized as described [6,11]. CPA 
and CPX were obtained from Research Biochemicals International 
(Natick, MA). The preparation and characterization of ‘251-labeled 
AB-MECA (N6-(4-aminobenzyl)-5’-&methylcarboxamidoadenosine) 
will be described elsewhere [9]. 
2.2. Locomotor activity 
Adult male mice (NIH Swiss strain, 25-30 g) were housed in groups 
of 10 animals per cage with a light-dark cycle of 12:12 h. The animals 
were given free access to standard pellet food and water and were 
acclimatized to laboratory conditions for 24 h prior to testing. Each 
animal was used only once in the activity monitor. 
Locomotor activity of individual animals was studied in an open 
field using a Dig&an activity monitor (Omnitech Electronics Inc., 
Columbus, OH) equipped with an IBM-compatible computer. The 
computer-tabulated measurements represent multivariate locomotor 
analysis with specific measures, such as simultaneous measurements 
of ambulatory, rearing, sterotypical, and rotational behaviors. Data 
was collected in the morning, for three consecutive intervals of 10 min 
each, and analyzed as a group. Statistical analysis was performed 
using Student’s t-test. The results are reported as mean f S.E.M. for 
each point. All drugs were dissolved in a vehicle consisting of a 20:80 
v/v mixture of Alkamuls EL-620 (RhBne-Poulenc, Cranbury, NJ) and 
phosphate-buffered saline, except for CSC, which was dissolved ini- 
tially in DMSO and diluted in at least 20 volumes of vehicle. Drugs 
were administered i.p. in a volume corresponding to 5 ml/kg body 
weight. Where applicable, the antagonist was injected 10 min before 
the agonist. After injection of agonist, the mouse was placed in the 
activity monitor for 5 min before data collection was begun. 
2.3. Membrane preparation 
Twenty white male mice (NIH Swiss strain, 25-30 g) were killed by 
cervical fracture. Brains were rapidly removed, placed in ice-cold 50 
mM Tris-HCl buffer (PH 7.4), and cortex, cerebellum, hippccampus, 
brain stem and striatum were dissected. Tissue was homogenized in 
20 ml of ice-cold 50 mM Tris-HCl buffer @H 7.4) using a Polytron 
(setting no. 6) for 10 s. The homogenates were centrifuged at 
35,000 x g for 15 min at 4°C. The pellets then were resuspended in 
fresh volume of the same buffer, homogenized with the Polytron and 
re-centrifuged. The linal pellet was stored at -7O’C before use in the 
receptor binding assay. For the binding assay membranes were diluted 
at a protein concentration of l-3 mg/ml. Protein concentrations were 
determined by the BCA protein assay reagents (Pierce Chemical Co., 
Rockford, IL) using bovine albumin as a standard. 
2.4. Radioligand binding 
[“‘I]AB-MECA binding to A, adenosine receptor in mouse brain 
membranes was performed in 50 mM Tris, 10 mM MgCl,, 1 mM 
EDTA buffer (pH 7.4) containing 100 ~1 membrane suspension with 
adenosine deaminase (3 units/ml) added. Where applicable, the A, 
component of binding was eliminated by the addition of 100 nM CPX 
to the medium. The final concentration of [‘251]AB-MECA ranged 
from 0.1 to 4 nM, while the final volume of the preparation was 0.5 
ml. Incubations were carried out in duplicate for 90 min at 25°C. 
Nonspecific binding was defined in the presence of 40 PM R-PIA 
(N6-R-phenylisopropyladenosine) andconstituted approximately 30% 
of the total binding. Binding reactions were terminated by filtration 
through Whatman GF/B filters using a Brandel M24R cell harvester 
(Brandel Gaithersburg, MD). Filters were washed three times with 3 
ml ice-cold buffer and placed in vials. Radioactivity was determined 
in a Beckman 5500B gamma-counter. 
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2.5. Analysis of data 
Linear fitting of Scatchard plots and the saturation experiments, 
analyzed by nonlinear egression using computer program GraphPad 
InPlot (Version 4.0, San Diego, CA), gave similar results for detenni- 
nation of K,, and B,,,,, values. Each experimental result is reported as 
mean + S.E.M. from three or four experiments. 
3. RESULTS 
The high affinity radioligand, [‘*‘I]AB-MECA [12], 
bound specifically to both A, and A, adenosine recep- 
tors in membranes prepared from regions of NIH Swiss 
mouse brains. Specific binding represented ca. 70% of 
total binding, with B,,, values (expressed as fmol specif- 
ically bound/mg protein in parentheses): hippocampus 
(215 + 17), cortex (159 + 15), cerebellum (120 + 5), and 
striatum (123 + 23). Scatchard analysis indicated Kd 
values ranging from 1.9 to 2.8 nM. The Ati selective 
antagonist 8-(3-chlorostyryl)caffeine (CSC) failed to 
displace specific binding of [‘*‘I]AB-MECA. The spe- 
cific binding consisted of two components, since the A, 
selective antagonist 1,3-dipropyl-Gcyclopentylxanthine 
(CPX) completely displaced the most but not all of the 
binding with high affinity (sigmoidal competition 
curves had K, values ranging from 2 to 8 nM). Thus, the 
majority of the specific binding of [‘?]AB-MECA was 
to high-affinity A, receptors. The residual binding, with 
was not displaced by CPX at concentrations as high as 
1 PM, represented binding to A3 adenosine receptors 
[9]. Low levels of A3 adenosine receptors (18% of total 
specific binding using 0.4 nM [‘251]AB-MECA in the 
presence of 100 nM CPX) were detected in the cerebel- 
lum and striatum, with even lower levels in the hip- 
pocampus and cortex (7-9% of total specific binding). 
A Scatchard analysis showed that in the presence of 100 
nM CPX the Kd for binding of [1251]AB-MECA to cere- 
bellar A, receptors was 1.39 + 0.04 nM with a B,,,ax of 
14.8 f 2.1 fmol/mg protein (n = 3) (Fig. 2). 
A potent (Ki 1.1 + 0.3 nM at rat brain A, receptors) 
and selective (50-fold less potent in binding to either A, 
or AZa rat brain receptors) A, agonist [l 11, 3-IB-MECA 
(2, Fig. l), was selected for in vivo studies. The locomo- 
tor effects in mice of 3-IB-MECA alone or in combina- 
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Fig. 1. Structures of adenosine agonists that have been used to charac- 
terize A, receptors. 
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Fig. 2. A representative saturation curve for binding at A, receptors 
in mouse cerebellar membranes using [“‘IJAB-MECA in the presence 
of 100 nM CPX. Conditions are described in section 2 (specific binding 
shown). The X;, value for binding to A, receptors was 1.39 f 0.04 nM 
with a B,,,, of 14.8 f 2.1 fmol/mg protein. 
tion with potent and selective Al and AZa receptor an- 
tagonists were examined. 3-IB-MECA administered i.p. 
in a dose range of 0.01 to 0.3 mg/kg was found to be 
locomotor depressant (total distance travelled) with a 
threshold dose of 0.01 mg/kg and maximal depression 
reached at - 0.1 mg/kg (Fig. 3). Unlike depression elicited 
by selective A, and A, agonists, the depression did not 
exceed 90% at the higher doses, but reached a plateau 
at ca. 60% below control level (Fig. 3). Vertical activity, 
stereotypy counts, and rotational movement were de- 
pressed in a dose dependent manner following admini- 
stration of 3-IB-MECA, however average distance per 
move and average speed were not changed significantly. 
Administration of 3-IB-MECA also caused rapid 
scratching behavior, whose frequency appeared to in- 
crease with the dose of the A, agonist. Since activation 
of A, receptors causes release of histamine in cultured 
mast cells, it was proposed that the scratching could be 
related to histamine. Coadministration of a histamine 
HI-antagonist, cyproheptadine at 10 mg/kg i.p. elimi- 
nated this behavior, while at 1 m&g dose of cyprohep- 
tadine the effect was only partial. 
The highly Al-selective antagonist CPX (0.25 mg/kg) 
completely reversed locomotor depression elicited by 
the potent A, agonist CPA at its determined ED,, value 
of 100 ,ug/kg i.p. (Fig. 4). CPX did not diminish the 
depressant effects of either the A,,-selective agonist 
APEC or 3-IB-MECA at doses chosen to cause compa- 
rable ca. 50% reduction in locomotor activity. 
The xanthine antagonist CSC is highly A,,-selective 
in binding assays, functional adenylate cyclase assays, 
and in vivo with respect to locomotor activity [6]. A 
dose of CSC of 1 mg/kg caused a small, statistically 
insignificant reversal of the 3-IB-MECA-mediated loco- 
motor depression (Fig. 4). Previously it was shown that 
the same dose of CSC caused a complete reversal of the 
behavioral depression elicited by APEC in the same 
experimental model [6]. 
4. DISCUSSION 
A3 receptors were found to be present in the mouse 
brain, with highest density in the cerebellum and stria- 
tum. Thus, the striatum, which is critical to the locomo- 
tor depressant effects of A,, agonists [21], contains A3 
receptors at a density at least lo-fold lower than AZ, 
receptors. Since previously reported levels of mRNA 
coding for A3 receptors in rat brain indicated the great- 
est density in hippocampus and cerebellum [14], there 
is either a species difference between rat and mouse, or 
the level of message is not entirely predictive of the level 
of receptor density. A, receptors are localized in high 
density in the hippocampus and appear to be involved 
in the cerebroprotective ffects of adenosine [16]. A3 
receptors were also detected in the hippocampus but at 
densities l-2 orders of magnitude lower than A, recep- 
tors. 
The non-reversal of locomotor depression by the A,- 
and A,,-adenosine antagonists is consistent with in vitro 
observations with rat A,-receptors, i.e. the inability of 
xanthines to antagonize at this site [&IO]. Both CPX 
and CSC are known to act centrally [6]. The lack of a 
selective A3 antagonist, to act peripherally or centrally, 
is a disadvantage in this study. Previous studies of loco- 
motor depression by A,- and A,,-adenosine agonists [3] 
have utilized both centrally-active xanthines and other 
xanthines, such as 8-sulfophenyltheophylline, that do 
not penetrate the blood brain barrier, to demonstrate 
the central nature of the behavioral effects. 
There is considerable interest in the therapeutic po- 
tential of selective A,-adenosine agonists and antago- 
nists to treat neurological and other CNS disorders. The 
cognition-enhancing [16,17], cerebroprotective [18], and 
anti-convulsant [19] effects of selective A,-adenosine 
agents have frequently been demonstrated. A,,-antago- 
nists may be useful in treating Parkinson’s disease [7]. 
The demonstration of a marked behavioral effect of A3 
receptor activation suggests that the A3 receptor may 
also represent a unique therapeutic target. 
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Fig. 3. Locomotor activity in male NIH Swiss mice. Effect of the 
A,-selective adenosine agonist 3-IB-MECA. *P value is < 0.05 vs. 
vehicle control (n = 619). 
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Fig. 4. Locomotor activity in mice following injection of an A,- (CPA, 
100 &kg), Azl- (APEC, 16 @kg), or A,- (3-IB-MECA, 100 @kg) 
selective agonist and the effects of coadministration of selective antag- 
onists (n = 619). Locomotor activity as a percent of control is shown 
for no antagonist (unshaded bars) or for coadministration of selective 
xanthine antagonists: CPX (shaded bars, A,, 0.25 mg/kg) or CSC 
(hatched bars, A,, 1 .O mg/kg). *P value < 0.05 vs. adenosine agonist 
alone. 
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